Outlook Therapeutics Inc share price logo

Outlook Therapeutics Inc Share Price

NASDAQ: OTLK

Small Cap

$0.20

-0.12

(-38.09%)

as on

Outlook Therapeutics Inc Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $0.16
    $0.22
    downward going graph

    20.00%

    Downside

    10.00%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.29
    $3.39
    downward going graph

    -45.00%

    Downside

    1595.00%

    Upside

    downward going graph

Outlook Therapeutics Inc share price movements today

Previous Close
$0.32
Open
$0.22
Volume
26.5M
Day's Low - High
$0.16 - $0.22
52 Week Low - High
$0.29 - $3.39

Outlook Therapeutics Inc Historical Returns

1 Month Return
-27.27 %
3 Month Return
-82.52 %
1 Year Return
-77.16 %
3 Year Return
-98.45 %
5 Year Return
-99.3 %

Outlook Therapeutics Inc Stock Fundamentals & Key Indicators

Check Outlook Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$29.2M

EPS (TTM)

-0.5467

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-3.51

Industry PE ratio

0

PEG Ratio

0

EBITDA

-58.8M

Revenue (TTM)

205.7K

Profit Margin

0.00%

Return On Equity TTM

-3.65%

Outlook Therapeutics Inc Stock Valuation

Track how Outlook Therapeutics Inc P/E has moved over time to understand its valuation trends.

Outlook Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-130.40x)

September 30, 2021

Industry (0.00x)

March 25, 2026

Today (-3.51x)

March 25, 2026

Highest (-0.59x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -3.51x

Outlook Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Outlook Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Outlook Therapeutics Inc image
Outlook Therapeutics Inc
BUY$29.2M-99.3%-3.510.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B126.75%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.49%29.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B58.91%17.6731.41%

Stock Returns calculator for Outlook Therapeutics Inc Stock including INR - Dollar returns

The Outlook Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Outlook Therapeutics Inc investment value today

Current value as on today

₹23,826

Returns

₹76,174

(-76.17%)

Returns from Outlook Therapeutics Inc Stock

₹85,714 (-85.71%)

Dollar Returns*

₹9,541 (+9.54%)

Analyst Recommendation on Outlook Therapeutics Inc Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.31% of analysts recommend a 'BUY' rating for Outlook Therapeutics Inc. Average target price of $4.83

Outlook Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Outlook Therapeutics Inc.

What analysts predicted

95.86%UPSIDE

Target Price

$4.83

Current Price

$0.2

Analyzed by

13 Analysts

Target

$4.83

Outlook Therapeutics Inc target price $4.83, a slight upside of 95.86% compared to current price of $0.2. According to 13 analysts rating.

Outlook Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Outlook Therapeutics Inc Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-63% versus previous 30 day period

Outlook Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
-
-
-
0
0
-
1
0
-1
Gross Profit
0
0
0
0
0
0
0
1
-1
-1
Operating Income
-12
-10
-18
-19
-22
-21
-12
-15
-17
-13
EBITDA
-16
-10
-18
44
5
-21
-12
-20
-14
-13
Interest Expense
2,142,773
2,142,773
3
-
72,929
-
0
0
0
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-12
-11
-114
44
5
17
-46
-20
-14
-23
Income Tax Expense
2,797
0
0
0
-
17,377,596
0
-
-1
-
Net Income
-12
-11
-114
44
5
17
-46
-20
-13
-23
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
3345.21%
10214.90%
0.00%
-1338.75%
14482.19%
1908.77%

Outlook Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Sep 2016
Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Total Revenue
2
3
3
8
5
-
-
-
0
1
Gross Profit
2
3
3
-15
0
0
0
0
0
0
Operating Income
-51
-35
-29
-36
-36
-51
-63
-53
-71
-67
EBITDA
-48
-30
-26
-31
-36
-51
-64
-57
-72
-63
Interest Expense
1
5
3
3
1
0
1
1
3
0
Depreciation
-
2
3
3
0
0
0
0
0
0
Income Before Tax
-53
-38
-33
-37
-38
-53
-66
-58
-75
-63
Income Tax Expense
0
0
-3
-3
-3
0
0
0
0
-1
Net Income
-53
-38
-30
-34
-35
-53
-66
-58
-75
-62
Net Profit Margin
-1788.66%
-1019.12%
-974.48%
-423.82%
-602.01%
0.00%
0.00%
0.00%
-44301.22%
-4416.22%

Outlook Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-11
-114
44
5
17
-46
-20
-13
-23,058,135
Operating Cash Flow
-13
-19
-19
-16
-10
-16
-11
-12
-14,939,111
Investing Cash Flow
-
-
-
0
-
0
0
-
-
Financing Cash Flow
0
56
4
0
1
18
13
11
15,533,450
Change in Cash
-13
36
-15
-17
-9
1
1
0
594,339

Outlook Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Net Income
-38
-46
-34
-35
-53
-66
-58
-75
-62,424,863
Operating Cash Flow
-15
-33
-32
-31
-54
-56
-42
-68
-51,829,437
Investing Cash Flow
0
-2
0
0
-
-
-
-
-
Financing Cash Flow
16
34
39
37
56
59
48
60
44,984,984
Change in Cash
0
-1
6
4
1
2
5
-8
-6,844,453

Global Institutional Holdings in Outlook Therapeutics Inc

Funds
Holdings
Schonfeld Strategic Advisors LLC
2.94%
Morgan Stanley - Brokerage Accounts
0.96%
Steward Partners Investment Advisory, LLC
0.82%
Scotia Capital Inc
0.09%
Marshall Wace Asset Management Ltd
0.36%
See all

Outlook Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 02 January

    Fri, 06:48 PM

    -

    Outlook Therapeutics stock hits 52-week low after FDA rejects Lytenava filing for wet AMD due to insufficient evidence.

Insights on Outlook Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 16.1% return, outperforming this stock by 93.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Outlook Therapeutics Inc has experienced a drawdown of -98.4%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 88.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, OTLK stock has moved down by -8.6%

About Outlook Therapeutics Inc

overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
OrganisationOutlook Therapeutics Inc
Headquarters111 S. Wood Avenue, Iselin, NJ, United States, 08830
IndustryHealth Technology
CEOMr. Robert Charles Jahr
E-voting on sharesClick here to vote

Key Management of Outlook Therapeutics Inc

Name

Title

Mr. Jedd Comiskey

Senior VP - Head of Europe

Mr. Robert Charles Jahr

President, CEO & Director

Mr. Lawrence A. Kenyon CPA

EVP, CFO, Treasurer, Secretary & Director

Mr. Joel Prieve

Senior Vice President of Licensing and M&A

Dr. Surendra Sharma M.D.

Senior Vice President of Medical Affairs

Dr. Jennifer M. Kissner Ph.D.

Senior Vice President of Clinical Development & Regulatory Affairs

FAQs

What is Outlook Therapeutics Inc share price today?

Outlook Therapeutics Inc share price today is $0.2 as on at the close of the market. Outlook Therapeutics Inc share today touched a day high of $0.22 and a low of $0.16.

What is the 52 week high and 52 week low for Outlook Therapeutics Inc share?

Outlook Therapeutics Inc share touched a 52 week high of $3.39 on and a 52 week low of $0.29 on . Outlook Therapeutics Inc stock price today i.e. is closed at $0.2,which is 94.10% down from its 52 week high and -31.03% up from its 52 week low.

What is Outlook Therapeutics Inc's market capitalisation today?

Outlook Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Outlook Therapeutics Inc Stock (OTLK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Outlook Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Outlook Therapeutics Inc Shares that will get you 7.5000 shares as per Outlook Therapeutics Inc share price of $0.2 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Outlook Therapeutics Inc Stock (OTLK) from India?

Indian investors can start investing in Outlook Therapeutics Inc (OTLK) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Outlook Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Outlook Therapeutics Inc share’s latest price of $0.2 as on March 25, 2026 at 1:29 am IST, you will get 50.0000 shares of Outlook Therapeutics Inc. Learn more about fractional shares .

What are the returns that Outlook Therapeutics Inc has given to Indian investors in the last 5 years?

Outlook Therapeutics Inc stock has given -99.3% share price returns and 28.4% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?